Clinical Trial Update: A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors [Phase 1, Phase 2]

View source ↗

Summary

A first-in-human Phase 1/2 trial of JAB-8263 in adults with advanced tumors is currently recruiting across multiple cancer types including lung cancer and other…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Castration-resistant Prostate Cancer
• Esophageal Squamous Cell Carcinoma
• Malignant Neoplasm
• Myelofibrosis
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Small Cell Lung Cancer

Drugs mentioned

• JAB-8263

Snippet

Sponsor: Jacobio Pharmaceuticals Co., Ltd. | Conditions: NSCLC, SCLC | Phase 1, Phase 2 | Status: RECRUITING